NCT07365410 2026-01-26
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
Clinical Trials
3 trialsNCT06861218 2025-03-06
Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT05805631 2024-05-01
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Taipei Veterans General Hospital, Taiwan
Phase 2 Not yet recruiting